Health

Bone Spurs: Causes, Symptoms, Diagnosis, and Treatment Options

Published

2 weeks ago

June 14, 2026

Why People Search for Bone Spurs

You get an X-ray for heel pain, a stiff neck, or a sore shoulder — and the report comes back mentioning bone spurs. For many people, that term sounds alarming. The word “spur” suggests something sharp and damaging, which makes it easy to assume the worst.

Table of Contents

The reality is more nuanced. Bone spurs are extremely common, often cause no symptoms at all, and in many cases require no treatment. But when they do press on nerves or limit joint movement, they can cause real, persistent discomfort that deserves proper attention.

This article explains what bone spurs actually are, why they form, where they commonly appear, and what your real options are when they cause problems.

What Are Bone Spurs?

Bone spurs, medically known as osteophytes, are smooth, bony projections that grow along the edges of bones, usually near joints. Despite the name, they are not typically sharp or jagged. They tend to develop gradually and are often smooth extensions of the existing bone surface.

They form as the body’s response to pressure, friction, or joint damage over time. When cartilage breaks down or a joint becomes stressed repeatedly, the body tries to stabilize the area by laying down extra bone. That extra bone is a bone spur.

The medical term osteophyte comes from the Greek words for bone (osteon) and plant (phyton) — essentially meaning “bone growth.” That framing captures their nature well. They are organic growths, not foreign objects or fractures.

What Causes Bone Spurs?

The most common underlying cause is osteoarthritis. As the cartilage cushioning a joint gradually wears away, bones begin to rub against each other more directly. The body responds by attempting to repair or reinforce the joint, and bone spurs are part of that process.

Other contributing factors include:

Aging. Bone spurs become more common with age simply because joints accumulate more wear over time. Most people over 60 have at least some osteophyte formation, though many never experience symptoms.

Repetitive stress. Activities that place repeated strain on a joint — running, certain manual labor jobs, or sports involving jumping and landing — can accelerate the process. The heel is particularly susceptible because of the constant load it bears.

Plantar fasciitis. Chronic inflammation of the plantar fascia, the band of tissue running along the bottom of the foot, can lead to heel spurs. The body responds to the tension at the point where the fascia attaches to the heel bone by forming extra bone.

Injury. A fracture, ligament tear, or joint injury can trigger bone spur formation during the healing process.

Poor posture. Certain postural patterns, especially in the spine, can create uneven mechanical stress on vertebrae and discs, contributing to spinal osteophytes over time.

Nutritional factors. Calcium metabolism plays a role in bone formation generally, though bone spurs are not simply the result of excess dietary calcium.

Where Bone Spurs Commonly Form

Bone spurs can develop on virtually any bone in the body, but certain locations are far more common than others.

Heel Bone Spurs

The heel is probably the most frequently discussed location. Heel spurs form on the underside of the calcaneus — the heel bone — typically at the point where the plantar fascia or Achilles tendon attaches. They are closely associated with plantar fasciitis, though the two conditions are distinct.

Many people assume their heel pain is caused by the spur itself pressing into tissue with each step. In reality, the inflammation in the surrounding tissue — not the spur — is usually what hurts. The spur and the plantar fasciitis often coexist, but treating the inflammation is generally what brings relief.

Spine (Cervical and Lumbar)

Spinal bone spurs, also called vertebral osteophytes, are extremely common with age. They form on the edges of vertebrae, often in the cervical spine (neck) or lumbar spine (lower back).

Most spinal bone spurs cause no symptoms. However, when they grow large enough to narrow the spaces through which spinal nerves pass — a condition called spinal stenosis — they can cause pain, numbness, tingling, or weakness radiating into the arms or legs. Spurs in the cervical spine may press on nerves going into the arms. Spurs in the lumbar region can affect the sciatic nerve, contributing to sciatica.

Shoulder

Bone spurs in the shoulder typically form under the acromion, a part of the shoulder blade. When they narrow the space that the rotator cuff tendons pass through, they can cause a condition called shoulder impingement — where the tendons are repeatedly pinched during arm movement. Left unaddressed, this can eventually contribute to rotator cuff tears.

Knee

The knee is a common site for osteophytes, especially in people with knee osteoarthritis. Bone spurs here can limit the range of motion and contribute to the joint stiffness and pain that characterize knee arthritis. They are often visible on X-rays as irregular bony projections at the edges of the knee joint.

Hip

Hip bone spurs are frequently associated with femoroacetabular impingement (FAI), a condition where abnormal bone growth around the ball or socket of the hip joint causes friction during movement. This can restrict range of motion and lead to cartilage damage if not addressed.

Finger Joints

Heberden’s nodes and Bouchard’s nodes — bony enlargements at the finger joints — are essentially bone spurs associated with hand osteoarthritis. They are visible and palpable lumps at the joints, more common in older adults and often hereditary.

Symptoms: When Bone Spurs Cause Problems

The majority of bone spurs never cause any symptoms. People walk around with them for years, or entire lifetimes, without knowing they are there. They are frequently discovered incidentally on an X-ray taken for another reason.

When bone spurs do cause symptoms, it is usually because they are pressing on nearby structures — nerves, tendons, or other soft tissue. The specific symptoms depend entirely on where the spur is located.

Common symptoms when bone spurs become problematic:

Pain — often a dull ache at or near the affected joint, which may worsen with activity
Stiffness — particularly in the morning or after sitting for extended periods
Reduced range of motion — the joint simply cannot move through its full arc
Numbness or tingling — when a spur presses on a nerve, sensation changes in the area the nerve serves
Weakness — prolonged nerve compression can reduce muscle strength
Tenderness — the area around the spur may be sore to the touch

A key point: the size of a bone spur does not reliably predict whether it causes symptoms. A relatively large spur in a spacious area may never cause trouble, while a small spur in a tight space near a nerve can cause significant pain.

How Bone Spurs Are Diagnosed

Diagnosis typically begins with a physical examination. A doctor will ask about symptoms, assess range of motion, and check for areas of tenderness. Based on the history and exam, imaging is usually ordered to confirm the diagnosis.

X-ray is the standard first step. Bone spurs are generally visible on plain X-rays as bony projections at the edges of joints or along vertebrae. X-ray is fast, widely available, and usually sufficient to identify osteophytes.

MRI (Magnetic Resonance Imaging) provides more detail about soft tissue structures. If a bone spur appears to be pressing on a nerve or tendon, an MRI can show exactly what is happening in the surrounding area and helps guide treatment decisions.

CT scan is sometimes used when more precise bone detail is needed, particularly for complex spinal cases.

Nerve conduction studies or electromyography (EMG) may be ordered when nerve compression is suspected, to assess how well nerves are functioning.

Treatment Options for Bone Spurs

The approach to treatment depends entirely on whether the bone spur is causing symptoms. If it is not causing any problem, no treatment is needed. Monitoring is appropriate, and many people simply watch and wait.

When symptoms are present, treatment generally starts conservatively and progresses only if less invasive approaches do not provide sufficient relief.

Conservative (Non-Surgical) Treatments

Rest and activity modification. Reducing or temporarily stopping activities that aggravate symptoms often provides significant relief, particularly for heel spurs and shoulder impingement.

Physical therapy. Targeted exercises can strengthen the muscles around an affected joint, improve flexibility, reduce mechanical stress, and relieve pressure on nearby nerves or tendons. Physical therapy is often the most effective first-line treatment for bone spur-related pain.

Stretching. For heel spurs associated with plantar fasciitis, regular stretching of the calf muscles and plantar fascia can dramatically reduce discomfort.

Orthotics and footwear. Supportive shoe inserts can redistribute pressure away from a heel spur. Proper footwear reduces impact forces at the heel.

Over-the-counter pain relief. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen can help manage pain and reduce inflammation around the spur. These medications treat symptoms, not the spur itself.

Ice and heat. Ice is useful for managing acute flare-ups of pain and swelling. Heat may help loosen stiff joints before activity.

Corticosteroid injections. When inflammation is significant and conservative measures are not providing adequate relief, a corticosteroid injection directly into the affected area can provide more substantial, though usually temporary, symptom relief.

Surgical Treatment

Surgery for bone spurs is relatively uncommon and is reserved for cases where symptoms are severe, persistent, and have not responded to months of conservative treatment.

Recovery times, risks, and outcomes vary significantly depending on the location and extent of the surgery. Surgery is generally effective when conservative options have been exhausted and the spur is clearly causing the problem, but it does not prevent new bone spurs from forming elsewhere over time.

Common Misconceptions About Bone Spurs

Bone spurs are always painful

Most bone spurs cause no pain whatsoever. Pain occurs only when the spur compresses a nerve, tendon, or other tissue. Many people live with osteophytes on their X-rays their entire lives without any discomfort.

The spur itself is what hurts

Usually not. In the case of heel spurs, for example, the pain comes from the inflamed plantar fascia, not from the spur pressing into soft tissue like a tack. Removing the spur without addressing the inflammation often does not resolve the pain.

Eating too much calcium causes bone spurs

Bone spurs are not caused by dietary calcium intake. They result from mechanical stress and the body’s response to joint damage. Normal dietary calcium does not cause osteophytes.

If I have a bone spur, I need surgery

The vast majority of bone spurs, even symptomatic ones, can be managed effectively without surgery. Surgery is considered only when symptoms are severe and conservative treatments have failed over an extended period.

Bone spurs will keep growing and eventually cripple me

Bone spurs do not inevitably grow large or progressively disable someone. Many remain stable for years. The key is addressing the underlying joint degeneration or mechanical stress, which may slow further development.

Real-World Examples

Consider someone in their mid-50s who notices persistent heel pain every morning when they first step out of bed. After a few minutes of walking, the pain eases. An X-ray shows a heel spur and signs consistent with plantar fasciitis. This person does not need surgery. Calf stretching, a supportive shoe insert, and temporary reduction in high-impact activity often resolves this kind of pain within weeks to months.

Or think about a desk worker in their 60s who starts experiencing tingling down the left arm into the fingers, along with neck stiffness. An MRI reveals cervical bone spurs narrowing the foramen — the exit points for nerve roots in the neck. Physical therapy focused on neck mobility, posture correction, and nerve-gliding exercises is the appropriate starting point, with imaging follow-up if symptoms do not improve.

These examples illustrate why the same diagnosis — bone spurs — looks completely different depending on where the spur is and what it is pressing on.

Key Facts

Bone spurs (osteophytes) are smooth bony projections that form along bone edges, usually near joints.
Osteoarthritis is the most common underlying cause of bone spur formation.
The vast majority of bone spurs cause no symptoms and require no treatment.
Symptoms occur when a spur compresses a nearby nerve, tendon, or other tissue.
Common locations include the heel, spine, shoulder, knee, hip, and finger joints.
X-ray is the standard imaging tool for diagnosing bone spurs.
Conservative treatments — physical therapy, stretching, orthotics, NSAIDs — resolve most symptomatic cases.
Surgery is reserved for severe, persistent cases that do not respond to conservative care.
Bone spur size does not reliably predict whether symptoms will occur.
Heel spurs are closely associated with plantar fasciitis, but the two conditions are distinct.

FAQ

Q1: What exactly is a bone spur?

Ans: A bone spur, or osteophyte, is a smooth bony projection that grows on the edge of a bone, usually near a joint. The body produces them as a response to chronic pressure, friction, or cartilage deterioration. They are extremely common, particularly with aging.

Q2: Do bone spurs go away on their own?

Ans: No. Once formed, bone spurs do not dissolve or disappear without intervention. However, they often remain stable and asymptomatic for long periods. Treatment focuses on managing symptoms, not removing the spur — which is only done surgically when absolutely necessary.

Q3: Are bone spurs serious?

Ans: For most people, bone spurs are not serious. They are very common and usually cause no problems. When they do press on nerves or tendons, they can cause significant discomfort, but even in those cases, most people respond well to non-surgical treatment.

Q4: Can bone spurs cause paralysis or permanent nerve damage?

Ans: Severe, untreated spinal bone spurs that significantly compress the spinal cord or major nerve roots can, in rare cases, cause serious neurological problems. This is one reason persistent numbness, weakness, or coordination problems related to neck or back pain warrant prompt medical evaluation rather than watchful waiting.

Q5: How long does it take to recover from bone spur treatment?

Ans: For conservative treatment, improvement often begins within a few weeks but full resolution can take several months, especially for heel spurs and shoulder impingement. Surgical recovery varies widely — from weeks for arthroscopic procedures to several months for more complex spinal surgery.

Q6: Can bone spurs come back after surgery?

Ans: Yes. Surgery removes the existing spur but does not address the underlying joint degeneration that caused it. New bone spurs can form over time, particularly if the mechanical stresses that contributed to the original spur are not addressed through ongoing physical therapy, weight management, or activity modification.

Q7: Who is most at risk for developing bone spurs?

Ans: People over 60, those with osteoarthritis, individuals in physically demanding jobs or sports, and people who are overweight — since extra body weight increases joint load — are among those most likely to develop symptomatic bone spurs.

Key Takeaways

Bone spurs are bony outgrowths that form near joints as the body responds to mechanical stress or cartilage damage.
Most bone spurs never cause symptoms and are discovered incidentally on imaging taken for other reasons.
Pain and symptoms occur only when a spur compresses nearby nerves, tendons, or tissue.
Common locations include the heel, neck, lower back, shoulder, knee, and hip.
Diagnosis is usually confirmed with X-ray; MRI provides additional soft tissue detail.
Conservative treatments — stretching, physical therapy, orthotics, anti-inflammatories — are effective for the majority of symptomatic cases.
Surgery is uncommon and is considered only when conservative treatment fails after an extended period.
Bone spurs do not dissolve on their own, but they can remain stable and manageable for years.

Conclusion

Bone spurs sound more threatening than they usually are. For most people who have them, they are a silent part of the normal aging process — present on X-rays, completely absent from daily life. When they do cause problems, those problems are usually manageable with physical therapy, proper footwear, activity adjustments, or medication.

The key is getting an accurate diagnosis so that treatment targets the right problem. Pain near a bone spur is not always caused by the spur itself, and treatment based on that misunderstanding may not help. Working with a physician to understand what is actually causing symptoms — and what the best approach is for the specific location and severity — gives the best chance of meaningful relief.

If you are experiencing joint pain, stiffness, or numbness and a healthcare provider mentions bone spurs, that finding is worth understanding clearly, not worrying about reflexively. Most of the time, the picture is far less alarming than the name suggests.

Health

Driving Theory Test Fail: How to Recover and Pass Next Time

Published

5 hours ago

June 29, 2026

Bryce Cotton

Introduction

So you’ve had a driving theory test fail — and right now it probably feels worse than it should. You studied, you practised, and it still didn’t go to plan. That’s genuinely frustrating, and you’re not alone in feeling it.

Table of Contents

Here’s what matters most: a driving theory test fail is not a dead end. It’s one of the most common outcomes for first-time candidates in the UK, and there’s a very clear path back to that pass. This guide walks you through exactly what happens next, why most people fail, and how to approach your retake with a real chance of success.

What Does a Driving Theory Test Fail Actually Mean?

The UK theory test has two separate sections: 50 multiple-choice questions and 14 hazard perception video clips. You need to pass both in the same sitting.

The pass marks are:

Multiple choice: 43 out of 50
Hazard perception: 44 out of 75

If you fall short on either section — even by one mark — the whole test is recorded as a fail. Your scores from a failed attempt do not carry over to your next sitting.

Direct Answer: What Happens After a Theory Test Fail?

After a driving theory test fail, you receive a feedback sheet showing which topic areas cost you marks. Your test fee (£23) is not refunded. You must wait at least 3 working days before rebooking. There is no limit on how many times you can retake the test. Once you do pass, your certificate is valid for 2 years.

Why Do Most People Fail the Theory Test?

Understanding the real causes of failure is the fastest way to fix them before your retake.

Not Enough Revision Time

Many candidates underestimate how broad the question bank is. The DVSA draws questions from a wide range of categories — road signs, speed limits, motorway rules, vehicle safety, and more. Surface-level revision rarely covers enough ground.

Weak Hazard Perception Skills

The hazard perception section catches a lot of candidates off guard. It tests your ability to spot developing hazards in video clips — situations where risk is growing, not just hazards that have already appeared. Clicking too early, too late, or in repetitive patterns reduces your score. The system is also designed to detect random clicking, which results in a zero for that clip.

Misreading Questions

Several multiple-choice questions are deliberately worded to test careful reading. Words like “least likely,” “should not,” or “most dangerous” completely change which answer is correct. Under time pressure, it’s easy to miss these and pick the wrong option.

Gaps in Specific Topics

Speed limits in different road types, stopping distances, motorway rules, and visually similar road signs are consistently among the areas where candidates lose marks. If your revision didn’t cover every category in depth, those gaps show up on results day.

Test Anxiety

Some candidates know the material well but still underperform because of nerves. The exam environment — timed, formal, unfamiliar — affects focus and recall. This is a fixable problem, but it requires practising in conditions that replicate the test, not just reading notes at home.

What to Do After a Driving Theory Test Fail

Step 1: Review Your Feedback Sheet

After every failed attempt, you receive a breakdown of which topic categories you lost marks in. This is the most important starting point for your revision. Don’t start from scratch — target the specific areas flagged in your results.

Step 2: Use Official DVSA Study Materials

The Highway Code is the foundation. Everything in the multiple-choice section traces back to it. DVSA-approved revision apps and the official question bank are the most reliable tools — third-party sites may include outdated or inaccurate questions.

Step 3: Practise Hazard Perception Separately

Hazard perception requires a different kind of preparation from the multiple choice. Work through official DVSA practice clips and focus on clicking as hazards develop — not after they’ve fully formed. The scoring system rewards early identification. Aim to understand the rhythm of the section, not just click instinctively.

Step 4: Take Full Timed Mock Tests

Reading notes and answering individual questions is not the same as sitting through 50 questions back-to-back under time pressure. Full mock tests in timed conditions build stamina, improve pace, and reduce the shock of the real exam environment.

Step 5: Connect Theory to Real Driving

One of the most effective ways to make theory knowledge stick is to apply it during practical lessons. Spotting road signs, anticipating hazard situations, and understanding junction rules in real traffic reinforces what you’re reading in a way that passive revision can’t.

Step 6: Rebook When You’re Ready — Not Just When You’re Allowed

The mandatory waiting period is 3 working days. But that doesn’t mean you should rebook the moment you’re allowed to. Sitting the test again with the same preparation is likely to produce the same result. Give yourself enough time to genuinely close the gaps, then book.

How Long Should You Wait Before Retaking?

There’s no single right answer, but most candidates benefit from at least 2–3 weeks of focused preparation before their next attempt. If you were very close to passing and your weak areas are narrow, you might be ready sooner. If you missed the pass mark by a significant margin, more time and a different revision strategy will serve you better.

Common Myths About Failing the Theory Test

You can only fail a certain number of times

False. There is no legal limit on attempts. You can retake the theory test as many times as needed.

A fail goes on your driving record

It doesn’t. Theory test results are not recorded on your driving licence and have no effect on insurance.

Your pass from one section counts next time

It doesn’t. Both sections must be passed together in the same sitting. Nothing carries over.

You should rebook immediately

The 3-day wait is a minimum, not a recommendation. Rebooking before you’re prepared almost always leads to another fail.

Clicking quickly on hazard perception is the strategy

No. Rapid or repetitive clicking is flagged by the system as cheating and can result in a zero for that clip.

Key Facts

Theory test fee: £23 per attempt (non-refundable)
Mandatory wait between attempts: 3 working days
No maximum number of attempts
Theory pass certificate valid for: 2 years
Multiple choice: 50 questions, 57 minutes, pass mark 43/50
Hazard perception: 14 clips, pass mark 44/75
Both sections must be passed in the same sitting
Around 40–50% of candidates do not pass on their first attempt

Frequently Asked Questions

Q1: How soon can I rebook after a driving theory test fail?

Ans: You must wait at least 3 clear working days. After that, you can book at any available slot — though waiting until you’re genuinely ready is more important than rebooking quickly.

Q2: Is there a limit on how many times I can retake?

Ans: No. You can retake the theory test as many times as you need to.

Q3: Does failing affect my provisional licence?

Ans: Not at all. You can continue driving with a supervising driver, having lessons, and practising on the road after a fail. The only restriction is that you cannot book a practical driving test without a valid theory pass certificate.

Q4: What if I passed the multiple choice but failed hazard perception?

Ans: You’ll need to retake both sections. Scores don’t carry over between attempts, regardless of which section you passed.

Q5: What happens if my theory pass certificate expires?

Ans: If you don’t complete your practical driving test within 2 years of passing the theory, the certificate expires. You’ll need to pass the theory again before rebooking the practical.

Q6: Why do so many people fail hazard perception?

Ans: Most candidates prepare thoroughly for the multiple choice but don’t practise hazard perception separately. The section requires a specific skill — identifying developing hazards early — that doesn’t come naturally without practice. Using official DVSA clips and understanding how the scoring works makes a significant difference.

Q7: Can nerves cause a fail even if I know the material?

Ans: Yes. Test anxiety is a real and common factor. The best defence is taking full-length mock tests in timed conditions before your real attempt, so the exam environment feels familiar rather than foreign.

Key Takeaways

A driving theory test fail means you didn’t meet the pass mark on at least one section — both must be passed together
Your fee is not refunded; you must wait 3 working days before rebooking
There is no limit on the number of retakes allowed
Use your feedback sheet to target specific weak areas, not revise everything from scratch
Hazard perception needs dedicated practice — it’s a different skill from the multiple choice
Full-length mock tests under timed conditions are the most effective preparation tool
Roughly half of all first-time candidates receive a fail — it’s far more common than most people realise
Your theory pass certificate is valid for 2 years once you earn it

Conclusion

A driving theory test fail is frustrating, but it’s also genuinely common. The test is designed to assess real knowledge and road awareness — not just the ability to recall answers under pressure. Most people who fail are closer to passing than they think.

The key is to avoid the temptation to rebook immediately without changing anything. Use your results breakdown, close the gaps it reveals, practise in realistic test conditions, and give hazard perception the dedicated attention it deserves. That combination gives you the strongest possible chance of walking out of your next test with a pass.

Health

Joe Tippens: The Cancer Story, the Fenbendazole Protocol, and What the Science Says

Published

2 weeks ago

June 13, 2026

Bryce Cotton

In 2016, an Oklahoma businessman named Joe Tippens was given roughly three months to live. His small-cell lung cancer had spread throughout his body — to his neck, stomach, liver, bladder, pancreas, tailbone, and right lung. Conventional medicine had reached its limits.

Table of Contents

Today, more than nine years later, Joe Tippens is alive and in remission.

His story has been read by people in over 60 countries. It has sparked thousands of conversations between patients and oncologists, prompted new laboratory research, and made a decades-old veterinary deworming drug one of the most searched substances in the world among cancer patients.

Whether you’re a patient researching options, a family member looking for answers, or simply someone trying to understand what the Joe Tippens story actually involves, this article lays out the full picture — what happened, what he took, what science currently says, and what to be cautious about.

Who Is Joe Tippens?

Quick Answer

Joe Tippens is an American businessman from Oklahoma who was diagnosed in 2016 with stage IV small cell lung cancer that had metastasized throughout his body. Given a terminal prognosis of approximately three months, he began taking fenbendazole — a veterinary antiparasitic drug — alongside supplements and his prescribed immunotherapy. Within months, his PET scans showed no evidence of cancer. As of early 2026, he remains alive and in complete remission, ten years after his original diagnosis.

Joe Tippens grew up in a small Oklahoma town in the late 1950s, the youngest of six children. He describes his upbringing as grounded in agriculture and family. By the time of his diagnosis, he was a working professional with no prior significant health history.

The diagnosis came in 2016. Small cell lung cancer is one of the most aggressive forms of the disease, known for rapid progression and poor survival rates. By the time it was identified, Tippens’ cancer had already spread far beyond the lungs. His doctors at MD Anderson Cancer Center told him he had roughly a 1% chance of survival and gave him a prognosis of about three months.

He enrolled in a clinical trial for a new immunotherapy drug called Keytruda (pembrolizumab), but given his prognosis, he believed it was unlikely to make a significant difference in time.

How Did Joe Tippens Discover Fenbendazole?

The story begins with a tip from a veterinarian acquaintance.

Tippens heard about research being conducted at Merck Animal Health, where scientists were studying fenbendazole — a broad-spectrum antiparasitic drug long used in veterinary medicine to deworm dogs, cats, and livestock. In the course of that research, the drug had shown unexpected effects on cancer cells in mice. The story of a scientist at Merck who was diagnosed with brain cancer, tried fenbendazole, and later showed a clean scan circulated among some medical circles.

Tippens decided he had nothing to lose. In January 2017, he began taking fenbendazole alongside a small set of supplements he added himself. He continued receiving Keytruda as part of the clinical trial throughout this period.

Three months later, his PET scan came back clean.

He shared his story publicly in 2019 through his blog, My Cancer Story Rocks (mycancerstory.rocks). Within weeks, it had been read across more than 60 countries. Searches for fenbendazole spiked dramatically worldwide — particularly in South Korea, where his story went especially viral and prompted national media coverage.

As of January 2026, Joe Tippens was alive and in complete remission — marking ten years since his original terminal diagnosis. In February 2026, he appeared publicly at the Annie Appleseed Cancer Conference in West Palm Beach, Florida.

What Is the Joe Tippens Protocol?

The regimen Tippens used has become widely known as the Joe Tippens Protocol or the Fenbendazole Cancer Protocol. It centers on four components.

The Original Protocol Components

1. Fenbendazole (Panacur C or Safeguard) The core of the protocol. Fenbendazole is an antiparasitic drug sold over the counter in pet stores as a dog dewormer. Tippens took 222 mg (one 1-gram packet of Panacur C) three days on, four days off per week. Over time, he updated his approach to daily use.

2. Curcumin A compound found in turmeric, taken at 600 mg per day in a bioavailability-enhanced form. Curcumin has been studied for various anti-inflammatory and potential anti-tumor properties in laboratory settings.

3. CBD Oil 25 mg per day. Tippens included CBD (cannabidiol) oil as part of his regimen. He has since noted this component of the original protocol.

4. Vitamin E (Tocotrienol form) 800 IU daily, originally included in the protocol. Tippens later removed vitamin E from his updated regimen in a July 2020 blog update, citing concerns about a particular interaction.

Important Context: Keytruda Was Also Being Used

One critical fact that is frequently overlooked in popular coverage of this story: Joe Tippens was simultaneously enrolled in a clinical trial for Keytruda (pembrolizumab), a checkpoint inhibitor immunotherapy drug. Keytruda has since become a standard-of-care treatment for several cancer types, including some forms of lung cancer, and is known to produce dramatic responses in certain patients.

This means it is scientifically impossible to attribute Tippens’ remission solely to fenbendazole. His recovery happened in the context of two simultaneous interventions — the conventional immunotherapy drug and the self-administered fenbendazole protocol. Neither he nor any researcher can say with certainty which factor was responsible, or how much each contributed.

This distinction matters enormously when interpreting the story.

What Is Fenbendazole, and How Might It Work Against Cancer?

Fenbendazole (chemical name: methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate) belongs to the benzimidazole family of antiparasitic drugs. It works in animals by binding to beta-tubulin, a protein involved in cell division. By disrupting tubulin, it prevents parasites from reproducing.

Researchers have been investigating whether this same mechanism could affect cancer cells, which also rely heavily on tubulin during division.

Proposed Mechanisms in Cancer Research

Laboratory and animal studies have proposed several ways fenbendazole might affect tumor cells:

Microtubule disruption: Similar to its anti-parasitic mechanism, fenbendazole may interfere with the assembly of microtubules in cancer cells, disrupting cell division. A 2018 study published in Scientific Reports confirmed this effect in human cell lines.

Glucose metabolism interference: Cancer cells consume glucose at an extraordinarily high rate — roughly 200 times faster than normal cells. Some preclinical research suggests fenbendazole may impair cancer cells’ ability to take up glucose, starving them metabolically.

Apoptosis induction: Several lab studies have found that fenbendazole can trigger programmed cell death (apoptosis) in cancer cell lines.

Proteasome disruption: Some evidence points to interference with the cellular machinery cancer cells use to manage protein turnover.

Anti-angiogenic effects: Early preclinical reports have noted possible reduction in tumor blood vessel formation, which could limit nutrient supply to tumors.

Cancer stem cell suppression: More recent research, including a 2025 study published in the journal Molecules, found that fenbendazole exhibited antitumor activity against cervical cancer stem cells in laboratory models.

What the Research Does NOT Yet Show

All of the above mechanisms are based on laboratory studies and animal models. No large randomized controlled clinical trial has yet tested fenbendazole as a cancer treatment in humans. This is the critical gap between what the preclinical evidence suggests and what has been clinically proven.

A 2021 case series documented three patients with genitourinary malignancies who showed complete responses with fenbendazole, either alone or combined with standard therapies. A 2025 review of approximately 170 anecdotal case reports noted tumor regression across various cancers. However, these reports carry significant limitations in terms of clinical rigor — they cannot establish cause and effect, control for confounding treatments, or account for survivorship bias.

In September 2024, a protocol combining fenbendazole, ivermectin, and mebendazole was published in the Journal of Orthomolecular Medicine — marking the first peer-reviewed publication of this type of combined antiparasitic approach for oncology. However, this remains early-stage research and does not constitute standard medical guidance.

What Regulatory Bodies and Medical Organizations Say

The FDA, the European Medicines Agency (EMA), and the American Cancer Society have each issued cautions about using fenbendazole as a cancer treatment. Their concerns center on:

The absence of controlled human clinical trial data confirming efficacy
Unknown long-term effects of human use at cancer-treatment doses
The documented risk of patients delaying or abandoning proven conventional therapies in favor of unproven alternatives
The difficulty of determining cause and effect in individual case reports

These are legitimate concerns. Cancer patients who replace conventional treatment — chemotherapy, immunotherapy, radiation, surgery — with fenbendazole risk losing their window for evidence-based interventions that have proven survival benefits.

At the same time, a growing number of integrative oncologists have begun reviewing the preclinical evidence and discussing fenbendazole as a possible complementary approach — not a replacement — under medical supervision.

Survivorship Bias: Why the Stories You Hear Skew Positive

One of the most important concepts to understand when reading about Joe Tippens or similar cases is survivorship bias.

When something appears to work dramatically for someone, that person shares their story. Thousands of people who try fenbendazole and do not experience benefit are far less likely to post about it online. The result is an information environment that over-represents positive outcomes relative to actual outcomes.

This is not unique to fenbendazole. It applies to virtually every anecdotal health intervention that spreads on social media. The stories that go viral are the exceptional ones — by definition.

That doesn’t mean Joe Tippens’ remission wasn’t real. It clearly was, and it’s documented through medical scans. But it does mean that one person’s outcome — even a remarkable one — is not reliable evidence of what most people can expect.

Common Misconceptions About Joe Tippens and His Protocol

“Joe Tippens was cured by fenbendazole alone.” He was simultaneously enrolled in a Keytruda immunotherapy trial. It is scientifically impossible to isolate fenbendazole as the sole cause of his remission. Keytruda is a powerful immunotherapy known to produce dramatic responses in some patients.

“Fenbendazole is a proven cancer treatment.” No large clinical trial has demonstrated this in humans. The preclinical evidence is genuinely interesting to researchers, but interest is not proof.

“If it worked for Joe, it will work for me.” Individual cancer cases vary enormously based on cancer type, stage, genetic profile, immune status, and other treatments being used. What happened in one case does not predict outcomes in others.

“Joe Tippens is dead.” This is false and stems from confusion with a different person. There is an obituary online for a “Joe Frank Tippens Jr.” who passed away in 2018 — this is not the same individual. As of January 2026, Joe Tippens is alive, in remission, and publicly active.

“The protocol is cheap and completely safe.” Fenbendazole is inexpensive compared to conventional cancer drugs, which is part of why it attracts interest. However, it has not been systematically studied for long-term human safety at cancer-treatment doses. Some patients have reported liver enzyme elevations. Safety in the context of specific conventional treatments — particularly certain chemotherapy regimens — has not been fully evaluated.

“Doctors are hiding this.” This framing is inaccurate and unhelpful. Oncologists who have reviewed the preclinical data tend to express genuine scientific interest while calling for rigorous trials — not suppression of the information. The issue is lack of clinical proof, not deliberate concealment.

Key Facts About Joe Tippens and Fenbendazole

Joe Tippens was diagnosed with stage IV small cell lung cancer in 2016 and given approximately three months to live
He was simultaneously enrolled in a clinical trial for Keytruda (pembrolizumab) when he began fenbendazole
His PET scans came back clean within months; he shared his story publicly in 2019
His blog was read by people in more than 60 countries within weeks of publication
As of January 2026, he is alive and in complete remission — ten years post-diagnosis
The Joe Tippens Protocol centers on fenbendazole (222 mg), curcumin (600 mg), and CBD oil (25 mg daily)
Fenbendazole is a veterinary deworming drug approved for animals, not humans for cancer treatment
Multiple laboratory studies have identified plausible anti-tumor mechanisms in cell and animal models
No large human clinical trial has confirmed fenbendazole’s efficacy as a cancer treatment
The FDA, EMA, and American Cancer Society have cautioned against using it as a replacement for proven treatments
Survivorship bias significantly shapes the anecdotal evidence circulating online
A 2024 peer-reviewed paper in the Journal of Orthomolecular Medicine marked the first publication of a combined antiparasitic cancer protocol including fenbendazole

What Should Someone With Cancer Know Before Considering This?

If you or someone you love has been diagnosed with cancer and is researching the Joe Tippens Protocol, here is what is most important to understand.

Talk to your oncologist first. Some oncologists are open to discussing fenbendazole as a complementary measure. Others are not. Either way, your treatment team needs to know what you are taking, because drug interactions and timing relative to conventional treatment matter.

Do not stop or delay conventional treatment. The most consistent message from oncologists — including those who find the preclinical data interesting — is that abandoning proven therapies for an unproven approach carries serious risk. Joe Tippens himself continued Keytruda throughout his fenbendazole protocol.

Monitor liver function. Fenbendazole has been associated with liver enzyme elevations in some cases. Regular blood work is important if you choose to use it.

Understand the limits of anecdotal evidence. One person’s experience — even a genuinely extraordinary one — is not a clinical trial. The people who did not have the same outcome are far less visible online.

Stay connected to reliable sources. Joe Tippens maintains his blog at mycancerstory.rocks and an active Facebook community. For scientific updates, peer-reviewed oncology databases and discussions with your medical team are the most reliable sources.

Frequently Asked Questions

Q1: Who is Joe Tippens?

Ans: Joe Tippens is an Oklahoma businessman who was diagnosed with terminal small cell lung cancer in 2016, given three months to live, and achieved complete remission within months of beginning fenbendazole alongside his prescribed immunotherapy. His story, shared on his blog My Cancer Story Rocks, went viral globally in 2019.

Q2: Is Joe Tippens still alive?

Ans: Yes. As of January 2026, Joe Tippens is alive and in complete remission — ten years after his terminal diagnosis. He appeared publicly at the Annie Appleseed Cancer Conference in February 2026.

Q3: What did Joe Tippens take?

Ans: His original protocol included fenbendazole (222 mg, three days on, four days off), curcumin (600 mg daily), CBD oil (25 mg daily), and vitamin E succinate — while simultaneously receiving Keytruda immunotherapy in a clinical trial.

Q4: What is fenbendazole?

Ans: Fenbendazole is a broad-spectrum antiparasitic drug used in veterinary medicine to treat parasites in dogs, cats, and other animals. It belongs to the benzimidazole drug class and is sold under brand names including Panacur C and Safeguard.

Q5: Has fenbendazole been proven to treat cancer in humans?

Ans: No. While preclinical studies show promising mechanisms, no large controlled human clinical trial has confirmed its efficacy as a cancer treatment. Medical authorities including the FDA and American Cancer Society caution against using it as a replacement for conventional therapy.

Q6: Why did Joe Tippens recover? Was it really fenbendazole?

Ans: This is the core scientific question that remains unanswered. Tippens was also taking Keytruda, a powerful immunotherapy known to produce dramatic remissions in certain patients. It is impossible from one case to determine how much each treatment contributed to his recovery.

Q7: Can anyone try the Joe Tippens Protocol?

Ans: Anyone can, but doing so without medical supervision and without maintaining conventional treatment carries risk. The most responsible approach is to discuss it with your oncology team, maintain conventional treatment, and monitor your health carefully if you choose to add fenbendazole.

Q8: Is there any ongoing clinical research on fenbendazole for cancer?

Ans: Yes. Researchers have been calling for formal clinical trials, and there is growing published preclinical literature. A 2024 peer-reviewed paper marked the first publication of a combined antiparasitic protocol for cancer in an established journal. Formal large-scale human trials remain the critical next step.

Key Takeaways

Joe Tippens is a real person who received a terminal cancer diagnosis in 2016 and remains alive and in remission as of 2026 — a genuinely extraordinary outcome
He took fenbendazole alongside Keytruda immunotherapy; both were part of his treatment during remission, making it impossible to isolate which caused the outcome
The Joe Tippens Protocol has become one of the most widely discussed alternative cancer approaches in the world, particularly among patients with late-stage or treatment-resistant disease
Fenbendazole has shown plausible anti-tumor mechanisms in laboratory and animal studies, but has not been validated in large human clinical trials
Regulatory bodies including the FDA and American Cancer Society caution against using it as a replacement for proven treatments
Survivorship bias shapes much of the positive anecdotal evidence online — the stories of those who did not benefit are far less visible
The most responsible path for any cancer patient is open dialogue with their oncology team before making any changes to their treatment plan

Joe Tippens’ story is remarkable by any measure. A man given three months to live is still here, nearly a decade later, speaking at cancer conferences and updating his blog. That alone is worth taking seriously.

What it doesn’t do, on its own, is prove a treatment. Science requires more than one story — even an extraordinary one. The most honest summary is this: the science is genuinely interesting, the evidence is preliminary, and no one yet knows enough to call fenbendazole a cancer cure. That work still needs to happen — in well-designed clinical trials, with careful monitoring, and transparent reporting of both successes and failures.

Until then, Joe Tippens’ story remains what it has always been: one remarkable case that raised important questions worth answering.